Skip to nav Skip to content

To inquire about our available technologies, call our office (813) 745-6828

VIEW A COMPLETE LIST OF TECHNOLOGIES

Name & Description Number
ULK3: ULK3 Inhibitors for the Treatment of Multiple Myeloma 22MA087
Immunomodulatory: Cereblon Degrading Molecules for the Treatment of Small Cell Lung Carcinoma and Melanoma 22MA084
Small Molecule Inhibitor: 3-(4-fluorophenyl)-N-phenylbenzamide Small-Molecule Inhibitors of the β-Catenin/BCL9 Protein-Protein Interaction 22MA004N
YAP1/OCT4: Small Molecule Inhibitors of the Protein Protein Interaction of YAP1 and OCT4 to Treat Cancer 21MB072
TAF1: Novel TAF1 PROTACS for the Treatment of Cancer 21MB065N
Antibodies: Novel Targeted Nanobodies Against HPV E6/E7 to treat HPV Related Cancers 21MA047N
p53: Combination Therapy of Hypothermia and Chemotherapy to Treat Temperature Sensitive p53 Mutant Tumors 21MA021N
BRD4 JAK2: Sultam (cyclic sulfonamide) BRD4 JAK2 Inhibitors to Treat Myelofibrosis 21MA020N
TROLLS: Inhibition Of TAp63 Regulated Oncogenic Long Noncoding RNAs (TROLLs) for the Treatment Of Cancer 20MB056
β-Catenin/BCL-9: Acyl sulfonamide-containing Small Molecules that Inhibit the β-catenin/BCL9 Protein-Protein Interaction 20MB051N
HPV E1: Novel Use for Aminocoumarins as HPV Helicase E1 Inhibitors to Treat Cancer 20MB046
CMG Helicase: Novel Replicative CMG Helicase Inhibitors (CMGi) to Treat Solid Tumors 20MB046T2
TAF1: Novel TAF1 Inhibitors for the Treatment of Cancer 20MB037N
ACK1: Small molecule ACK1 Inhibitors for the Treatment of Castrate Resistant Prostate Cancer 20MA015N
CDK12/CDK13: Novel Small Molecule Dual Inhibitors for CDK12/CDK13 for the Treatment of Triple Negative Breast Cancer 19MB064N
β-catenin/BCL9: Novel Small Molecules that Inhibit the β-catenin/BCL9 Interaction in Breast Cancer 19MB055 - VIDEO
Actinium Dotatate: Novel Atinum Dotatate Compounds with Low Toxicity and High Efficacy 19MA018N
β-catenin/TCF: Small Molecule Peptidomimetic Inhibitors of the Interaction of β-catenin and T-cell Factor 18MB076
Novel BRD4/JAK2 Dual Inhibitor Cancer Therapeutics 18MB053
β-catenin/TCF: Small Molecule Inhibitors of the Interaction of β-catenin and T-cell Factor 18MA018N
Ubiquitin Bispecific Antibody: Antibodies that Bring the E3 Ubiquitin Ligase into Close Proximity to Receptors to Induce the Receptor’s Degradation 17MB056N
XBP-1: XBP-1 Inhibitor B-I09 for the Treatment of Acute GVHD and Solid Organ Rejection 17MB051
β-catenin/BCL-9: Small Molecules that Inhibit the β-catenin/BCL9 Interaction 17MA014
HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Chronic Lymphocytic Leukemia (CLL) 16MA023N
Aurora/JAK2: Dual JAK2 and Aurora A Kinase Inhibitor for GVHD Prophylaxis 16MA005N
Ras/Raf: Stapled Peptides as Inhibitors of Mutant KRAS 15MA012
Ras: Small Molecules that Inhibit Mutant KRAS 15MA011
WEE1: Small Molecule WEE1 Inhibitor (WEIN-159) that Inhibits WEE1 Phosphorylation of H2B but Not Cdc2 to Treat Can 14MB092
HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Non-Hodgkin’s Lymphoma (NHL) 14MB086N
STAT3: Novel Small Molecule STAT3 Inhibitor for Cancer Treatment 12MB098
IRE-1: Novel Small Molecule Inhibitors of IRE-1 for the Treatment of B-cell Cancer 12MB089